Manufacturer record

NH Healthcare 16-E-2: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

1 batch manufactured by NH Healthcare 16-E-2 (Telangana) were declared Not of Standard Quality between March 2026 and March 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

1 record linked to NH Healthcare 16-E-2 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
1Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Mar 2026 to Mar 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

1
NSQ batches since 2026
1
Products affected
Description
Most common failure
Mar 2026
Latest alert

Flagged batches per year

2026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
ABSORBENT COTTON WOOL (IP) 722Mfg 2025-09 · Exp 2028-08 Description and Neps parametersDescription DCL,TelanganaState lab Mar 2026

Batches reported as suspected spurious under this label

CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.

ProductBatchReported byFirm's replyAlert
Trypsin-Chymotrypsin Tablets2KU6L055FDAL MaharashtraThe actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug.Jan 2026

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.